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Genetic Variation in the Human Promoter Alters Glucocorticoid
Signaling, Yielding Increased NPY Secretion and Stress Responses
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Objectives This study sought to understand whether genetic variation at the Neuropeptide Y (NPY) locus governs secretion
and stress responses in vivo as well as NPY gene expression in sympathochromaffin cells.
Background The NPY is a potent pressor peptide co-released with catecholamines during stress by sympathetic axons.
Genome-wide linkage on NPY secretion identified a LOD (logarithm of the odds ratio) peak spanning the NPY
locus on chromosome 7p15.
Methods Our approach began with genomics (linkage and polymorphism determination), extended into NPY genetic con-
trol of heritable stress traits in twin pairs, established transcriptional mechanisms in transfected chromaffin
cells, and concluded with observations on blood pressure (BP) in the population.
Results Systematic polymorphism tabulation at NPY (by re-sequencing across the locus: promoter, 4 exons, exon/intron
borders, and untranslated regions; on 2n  160 chromosomes of diverse biogeographic ancestries) identified
16 variants, of which 5 were common. We then studied healthy twin/sibling pairs (n  399 individuals), typing
6 polymorphisms spanning the locus. Haplotype and single nucleotide polymorphism analyses indicated that
proximal promoter variant 880 (2-bp TG/—, Ins/Del, rs3037354) minor/ allele was associated with sev-
eral heritable (h2) stress traits: higher NPY secretion (h2  73  4%) as well as greater BP response to environ-
mental (cold) stress, and higher basal systemic vascular resistance. Association of 880 and plasma NPY
was replicated in an independent sample of 361 healthy young men, with consistent allelic effects; genetic vari-
ation at NPY also associated with plasma NPY in another independent series of 2,212 individuals derived from
Australia twin pairs. Effects of allele 880 to increase NPY expression were directionally coordinate in vivo (on
human traits) and in cells (transfected NPY promoter/luciferase reporter activity). Promoter 880 interrupts a
novel glucocorticoid response element motif, an effect confirmed in chromaffin cells by site-directed mutagene-
sis on the transfected promoter, with differential glucocorticoid stimulation of the motif as well as alterations in
electrophoretic mobility shifts. The same 880 allele also conferred risk for hypertension and accounted for
approximately 4.5/approximately 2.1 mm Hg systolic BP/diastolic BP in a population sample from BP extremes.
Conclusions We conclude that common genetic variation at the NPY locus, especially in proximal promoter 880, dis-
rupts glucocorticoid signaling to influence NPY transcription and secretion, raising systemic vascular resistance
and early heritable responses to environmental stress, eventuating in elevated resting BP in the population. The
results point to new molecular strategies for probing autonomic control of the human circulation and ultimately
susceptibility to and pathogenesis of cardiovascular and neuropsychiatric disease states. (J Am Coll Cardiol
2012;60:1678–89) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.042From the *Departments of Medicine, Pharmacology and Psychiatry, and Institute for
Genomic Medicine, University of California at San Diego, San Diego, California;
†Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ‡Depart-
ment of Molecular and Experimental Medicine, the Scripps Research Institute, La
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October 23, 2012:1678–89 Functional Variants of NPYNeuropeptide Y (NPY), a 36-amino acid peptide neu-
rotransmitter, is produced/secreted by noradrenergic neu-
rons (both central and autonomic) as well as chromaffin cells
(1). The peptide has diverse functions, including roles in
immune response (2); regulation of food consumption (3);
and control of heart rate, vasoconstriction, coronary blood
flow, and ventricular function (4). The NPY also augments
vasoconstrictor effects of noradrenergic neurons. Like epi-
nephrine and norepinephrine, the release of NPY to the
circulation occurs during sympathetic activation after environ-
mental stress (5). Compared with the more rapid secretion
nd duration of catecholamine action, NPY is released by
ore intense and prolonged sympathetic activation, thus
arking more severe stress (6). Increased NPY signaling due to
levated NPY expression in the hypothalamus might contrib-
te to development of obesity and its related traits, Type II
iabetes, and cardiovascular disease (3). The NPY is also
nvolved in regulatory loops between the immune and adrenal
ystems in pathophysiological conditions wherein interleukin-
-beta secretion is activated, as in sepsis, rheumatoid arthritis,
tress, or hypertension (7,8). Moreover, NPY increases the
roportion of energy stored as fat and blocks nociceptive
ignals to the brain (9).
The effect of stress on blood pressure (BP) is thus of
ncreasing importance. Although hypertension is not a
imple consequence of stress, repeated stressors might even-
uate in systemic hypertension (10). Patients with hyperten-
ion often exhibit increased sympathetic activity (11,12),
nd people with sympathetic overactivity tend to develop
ypertension (13,14). In a rodent genetic model of stress
Rat Genome Database, Bioinformatics Research Center,
ilwaukee, Wisconsin), the Npy locus lies within the
onfidence interval for linkage to circulating corticosterone,
he rodent glucocorticoid (Stresp4). In light of the emerging
iology of NPY, we undertook the present study, with
enomic and computational tools to probe how heredity shapes
uman functional responses in the sympathetic neuroeffector
unction, with NPY as a likely focal point in the pathogenesis
f cardiovascular or neuropsychiatric disease.
Here we began with genomics (linkage and re-sequencing
or polymorphism determination) and proceeded to pheno-
yping of heritable proximal traits in twin pairs. Functional
tudies of NPY promoter polymorphism are evolving (15),
nd thus we established a novel transcriptional mechanism
n transfected cells, concluding with extension of the find-
ngs into disease in the population.
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ubjects and clinical character-
zation. Subjects were volun-
eers from southern California
San Diego area), and each sub-
ect gave informed, written con-
ent; the protocol was approved
y the institutional review board.
ecruitment procedures, definitions,
nd confirmation of subject diagno-
es are according to previous reports.
enomic deoxyribonucleic acid of
ach individual was prepared from
eukocytes in ethylenediaminetet-
aacetic acid–anticoagulated blood,
ith PureGene extraction columns
Gentra Biosystems, Minneapolis,
innesota).
olymorphism determination.
ee Online Methods. Character-
stics of the resequenced subjects
re given in Online Table 1.
etails of amplicons and poly-
erase chain reaction primers for
olymorphism determination and
enotyping are given in Online
ables 2 to 4.
CSD twin and sibling pairs.
rom 235 nuclear families, 399
ndividuals from twin and sibling
sib) pairs were recruited to con-
uct the following study. Zygosity
as confirmed by extensive micro-
atellite and single nucleotide
olymorphism (SNP) genotyping,
s described (16). Twins ranged in
ge from 15 to 84 years; 10% were
ypertensive. All of the twins in
hese allelic/haplotype association studies were self-identified
s of European (white) ancestry, to guard against the poten-
ially artifactual effects of population stratification.
PY replication in young American men. See Online
ethods.
PY replication in Australian twins. See Online
ethods.
rimary care population derived from extremes of BP
istribution. From a database of over 53,000 people in
outhern California, we ascertained 1,121 European-
ncestry individuals, of both sexes, from the highest and
owest 5th percentiles of a primary care population (17) in
P distribution. Evaluation included physical examination,
lood chemistries, hemogram, and extensive medical history
uestionnaire. Characteristics of the hypertensive and nor-
otensive groups are shown as Online Table 5.
Abbreviations
and Acronyms
BP  blood pressure
CI  cardiac index
DBP  diastolic blood
pressure
EMSA  electrophoretic
mobility shift assay
GR  glucocorticoid
receptor
GRE  glucocorticoid
response element
Ins/Del  insertion/
deletion
LD  linkage disequilibrium
LOD  logarithm of the
odds ratio
MAF  minor allele
frequency
NPY  Neuropeptide Y
QTL  quantitative trait
locus
SBP  systolic blood
pressure
sib  sibling
SNP  single nucleotide
polymorphism
SOLAR  Sequential
Oligogenic Linkage Analysis
Routines
SVRI  systemic vascular
resistance index
/  insertion/deletion
(2-bp Ins/Del, TG/—,
880) polymorphism at
human NPY promoter
position 880
(rs3037354)olecular genetics. See Online Methods.
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Functional Variants of NPY October 23, 2012:1678–89Systematic polymorphism determination at the NPY
locus. See Online Methods.
Genotyping of NPY variants. See Online Methods.
Genotyping of NPY promoter variant 880. See
nline Methods.
uman twin pair phenotyping. See Online Methods.
iochemical. For plasma NPY measurement, see Online
Methods.
Physiological (in vivo). See Online Methods.
Cardiac and vascular function at rest. See Online
ethods.
nvironmental (cold) stress test. See Online Methods.
omputation. See Online Methods.
tatistical analyses. Estimates are stated as mean  1
EM. Two-way analysis of variance or multivariable general
inear modeling was performed in SPSS (version 17.0,
PSS, Chicago, Illinois) to evaluate the significance of
ingle variants or interaction of variants during in vivo
ssociation studies as well as in vitro haplotype-specific NPY
romoter/reporter transfections. For twin pair analyses,
escriptive (genotype-specific mean  SEM) and inferen-
ial (chi square, p value) statistics were computed across all
f the twins, with generalized estimating equations in SPSS,
o account for correlated trait values within each twinship,
ith an exchangeable correlation matrix (18). Additional
ermutation tests (19) on 3  2 contingency tables (diploid
enotype vs. BP status), implemented with the Fisher exact
est, were used to confirm genotype effects on the dichoto-
ous BP trait. In addition to additive models, after inspec-
ion of clustering of the descriptive statistics (mean 
EM), heterozygotes and minor/major allele homozygotes
ere grouped together as needed, to test dominant/recessive
odels. Meta-analysis was carried out with the command
ETA, testing fixed effect (i.e., genotype) models in
TATA (version 12, StataCorp, College Station, Texas),
fter individual study regression analysis in SPSS (version
NPY Promoter Variant 880 rs3037354: Effects on Heritable ATable 1 NPY Promoter Variant 880 rs3037354: Effects on
Category/Trait
Trait H2 in Twins (n  338)
Mean  SEM p Value
Biochemical
Plasma NPY, pmol/l 0.73 0.04 3.08E-26*
Physiological/hemodynamic (resting)
SBP, mm Hg 0.45 0.06 2.07E-09*
DBP, mm Hg 0.51 0.06 7.18E-12*
HR, beats/min 0.31 0.07 3.94E-05*
CI, l/min/m2 0.71 0.04 2.51E-19*
SVRI, dynes/s/cm5/m2 0.55 0.06 7.70E-12*
SVI, ml/min/m2 0.66 0.05 1.81E-17*
Environmental stress (cold pressor test)
Delta-SBP, mm Hg 0.65 0.05 2.60E-16*
Delta-DBP, mm Hg 0.54 0.06 7.52E-11*
Heritability (h2) was estimated from variance components in twins, with Sequential Oligogenic Lin
stimating equation in SPSS (SPSS, Chicago, Illinois), with additive genetic models. *p  0.05.
CI  cardiac index; DBP  diastolic blood pressure; HR  heart rate; “Index”  hemodynamic value (C
pressure; SVI  stroke volume index; SVRI  systemic vascular resistance index.7, SPSS), incorporating individual study data to derive
ignificance as well as pooled genotype effect size (beta, or
lope/allele) and its SE.
enome-wide linkage analysis. See Online Methods.
ata transformation. See Online Methods.
eritability of phenotype expression in vivo. See Online
ethods.
aplotypes and linkage disequilibrium. See Online
ethods.
arker-on-trait association. See Online Methods.
romoter motif analyses. See Online Methods.
PY promoter/luciferase reporter activity assays. See
nline Methods. A schematic of NPY promoter/luciferase
eporter constructions is given in Online Figure 1.
ffect of glucocorticoid and PAX6 on NPY promoter/
uciferase reporter activity. See Online Methods.
lectrophoretic mobility shift assays. See Online Methods.
ligonucleotides for electrophoretic mobility shift assay
EMSA) are given in Online Table 6.
esults
utonomic trait heritability in twin pairs. Basal/resting
lasma concentration of NPY was under substantial genetic
ontrol, with heritability (h2)  0.73  0.04 (p  3.1E-26)
Table 1). Heritability was also significant for resting
ystolic blood pressure (SBP) (h2  0.45  0.06, p 
0.001), diastolic blood pressure (DBP) (h2  0.51  0.06,
 0.001), heart rate (h2  0.31  0.07, p  0.001),
cardiac index (CI) (h2  0.71  0.04, p  0.001), systemic
ascular resistance index (SVRI) (h2  0.55  0.06, p 
.001), and stroke volume index (h2  0.66  0.05, p 
0.001). During environmental (cold) stress, heritability was
also established for SBP change (h2 0.65 0.05, p 0.001)
as well as DBP change (h2  0.54  0.06, p  0.001).
mic Traits in Twins and Sibsitable Autonomic Traits in Twins and Sibs
880 Diploid Genotype (n  399)
p Value/ (186) / (175) / (38)
72.0 3.08 74.3 3.3 132.7 1.6 4.2E-5*
133 1.2 132 1.1 133 1.6 0.658
72.6 0.9 71.8 0.8 71.8 1.3 0.702
70.5 1.0 68.4 0.9 64.3 1.5 0.002*
2.77 0.05 2.70 0.05 2.51 0.06 0.004*
798.7 18.8 845.3 21 879.0 31.3 0.039*
39.8 0.4 39.5 0.4 39.1 0.6 0.576
14.3 1.5 15.1 2.5 16.0 2.5 0.786
10.4 1.1 9.3 1.0 14.6 1.7 0.0072*
nalysis Routines. Descriptive statistics were computed in twins and siblings (sibs), by generalized
2utonoHer
kage AO or SVR) normalized to body surface area (in m ); NPY  Neuropeptide Y; SBP  systolic blood
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October 23, 2012:1678–89 Functional Variants of NPYGenome-wide linkage for NPY secretion in twin and sib
pairs. Multi point sib-pair linkage analysis of plasma NPY
concentration revealed a peak logarithm of the odds score of
4.27 at 34 cmol/l on chromosome 7p15; of note, the NPY
locus itself is within the linked region (Fig. 1A), suggesting
that NPY itself might be a cis-QTL for NPY expression and
secretion.
Systematic polymorphism determination across the NPY
locus. In 80 individuals of 4 diverse biogeographic ances-
tries, we identified 14 SNPs, one 2-base insertion/deletion
(Ins/Del), and 1 single-base Ins/Del, in 6 amplicons span-
ning a 3,219-base pair (bp) footprint over the approximately
8-kbp locus plus proximal promoter (Fig. 1B, Online Table 7).
Of these, 5 polymorphisms are common (at minor allele
frequency [MAF] 20%); in the proximal promoter, there
is 1 common SNP (rs16147, C-399T, MAF  47.6%) and
1 common 2-base Ins/Del (rs3037354, 880 Ins/Del
TG/—, MAF  19.3%). We identified 2 non-synonymous
NPs: 1 in the signal peptide (rs16139; T1071C, Leu7Pro;
AF: 1.9%), and the other in exon-4 (T7493C, Met95Thr;
.6%). Each of the 2 common polymorphisms in the NPY
romoter (880 and C399T) potentially interrupts
ranscription factor binding motifs (Fig. 1C).
air-wise linkage disequilibrium. To visualize patterns of
NP associations, pair-wise correlations among the 5 com-
on SNPs (MAF 20%) were quantified as linkage dis-
quilibrium (LD) parameter D’ by Haploview (20) across
he NPY locus. A single block of LD was maintained across
uch of locus (D’0.8) in both whites and Asians, whereas
n blacks and Hispanics, the 2 promoter SNPs also remain
n 1 block (Online Fig. 2).
PY genetic variation and stress responses in twin and
ib pairs. Here we studied stress/BP phenotypes in a
ample of twin/sib pairs of European ancestry.
PY haplotypes and heritable plasma NPY and BP
hanges to stress in twins. Given the relatively high degree
f LD across the gene (Online Fig. 2), we began with
aplotypes to span the locus, with 5 common polymor-
hisms (rs3037354, rs16147, rs16140, rs5573, and rs5574,
AF 20%) and 1 SNP in the signal peptide (rs16139
eu7Pro, MAF  2%), each in Hardy-Weinberg equilib-
ium (Online Tables 8 and 9), thus encompassing structural/
unctional domains across the gene (promoter, exons, in-
rons). In the twin/sib pairs, NPY displayed 3 common
aplotypes (Online Table 10), among which the second-
ost common—TGTGC—was associated with plasma
PY concentration as well as BP change during cold stress
Fig. 2A). Occurrence of haplotype TGTGC elevated
lasma NPY from 76.3  1.97 pmol/l to 91.1  5.42
mol/l (by approximately 19%, p  0.01), whereas DBP
ncreased from 10.0  0.7 mm Hg to 14.7  1.9 mm Hg
by approximately 47%, p  0.016) (Fig. 2A).
PY promoter polymorphism 880: effects on heritable
iochemical and physiological “intermediate” traits in twins.
n the twin/sib sample, the promoter Ins/Del polymorphism
ithin the NPY haplotype block displayed the peak effect on sraits: 880 was associated with plasma NPY as well as BP
hange during the cold stress test (change in DBP) (Fig. 2B,
able 1). The / homozygotes displayed mean NPY of
00.1  7.8 pmol/l, whereas  carriers (/ or /) were
iminished, at 71.8  2.8 pmol/l (chi-square  12.26, p 
.00046). The / homozygotes displayed a cold-stress DBP
ncrement of 14.6  1.7 mm Hg, whereas  carriers (/ or
/) exhibited a change in DBP of 9.8  0.8 mm Hg
chi-square  7.22, p  0.0072).
Delta880 exhibited reciprocal effects on basal hemo-
ynamics: / homozygotes displayed the lowest SVRI
SVR/body surface area) values, at 798.7  18.8 dynes/s/
m5/m2; whereas / homozygotes had the highest SVRI
values, at 879.0  31.3 dynes/s/cm5/m2, thus increasing
resistance by approximately 10.1% (Fig. 2C). By contrast,
/ homozygotes displayed the highest CI values, at 2.77
0.05 l/min/m2; while / homozygotes had the lowest CI
alues, at of 2.51  0.06 l/min/m2, thus decreasing CI by
pproximately 9.4%. In each case (SVRI and CI), heterozy-
otes displayed intermediate values, suggesting an additive
ffect of 880 on these traits. From the distribution of p
alues of tests of 880 on these correlated twin traits, we
stimated (see Methods) that a p value of 0.05 corresponded
o a False Discovery Rate of 0.067.
eplication of NPY promoter polymorphism 880
ffect on plasma NPY. In 361 healthy young males of the
arine Resilience Study, resting plasma NPY was signifi-
antly associated with 880 genotype: betaADD SE
.86  2.47, PADD  1.55  10
3; betaDOM  SE 
12.14  3.164, PDOM  1.47  10
4 (Table 2). Meta-
nalysis combining the twin/sib pairs and Marine Resilience
tudy samples in an additive model indicated allelic effects
onsistent in magnitude (beta) and direction (sign on slope)
cross groups; the overall slope of the meta-analysis regres-
ion (beta)  7.492 with SE (of beta)  1.769, p  0.0001.
In a second replication, 2,212 Australian twins phenotyped
or plasma NPY and subjected to genome-wide association,
ns880Del was not typed, but nearby variant rs16139
Exon-1, Leu7Pro) was available (hence, this was not an exact
eplication). By regression, T-allele beta 0.226, SE (of beta)
.094; the result was significant at p  0.016, and the
irectional effect of the T-allele was the same in Australia as in
he haplotype bearing the T-allele in the San Diego studies
TGTGC) (Fig. 2A). A separate test of Leu7Pro in the San
iego subjects confirmed its effect on plasma NPY (p 0.034),
ith the same directional effect on the NPY trait (TC).
PY promoter motifs: computational disruption by common
ariants 880 (glucocorticoid response element motif)
nd C-399T (PAX6 motif). The 880 (2-bp, TG/—,
ns/Del; rs3037354) variant lies in a region relatively conserved
cross species (especially in primates) with a partial match
8/12 bp) for a consensus glucocorticoid response element
GRE) motif and the insertion displaying a superior match
Figs. 1C and 3A).
C-399T (rs16147) also lies in a region relatively con-
erved across species, particularly in primates, with a partial
1682 Zhang et al. JACC Vol. 60, No. 17, 2012
Functional Variants of NPY October 23, 2012:1678–89Figure 1 Human NPY Genetic Diversity and NPY Expression
(A) Neuropeptide Y (NPY) secretion: cis-quantitative trait loci (QTL) by sibling (sib)-pair linkage. In a linkage study of plasma NPY concentration in sib pairs with 730 mic-
rosatellite markers, chromosome 7p15 displayed a peak logarithm of the odds (LOD)  4.27 at 34 cmol/l, with the NPY gene as a positional candidate locus beneath
the main peak. (B) Polymorphism discovery across the human NPY locus: re-sequencing strategy. There are 4 exons at the NPY locus. Five polymerase chain reaction
amplicons spanned the promoter and coding regions. Human/mouse homology (VISTA Tools for Comparative Genomics) is shown for evolutionarily conserved regions,
suggestive of functional importance. Red bars in the single nucleotide polymorphism (SNP) discovery panel denote polymorphisms with minor allele frequency (MAF)
20%. (C) Domains and motifs in the NPY promoter. Functional domains in the core/proximal promoter (such as the TATA box, and G/C-rich regions) were invariant in
80 people (2n  160 chromosomes) subjected to systematic polymorphism determination by re-sequencing. Two very common polymorphisms (MAF 20%) occur in the
proximal promoter: Ins880Del and C-399T. The 880 Ins/Del variant lies in a GRE transcriptional control motif (892/878), whereas C-399T lies in a recognition
motif for PAX6 (402/393). Del  deletion; Ins  insertion; NCBI  National Center for Biotechnology; SOLAR  Sequential Oligogenic Linkage Analysis Routines.
1683JACC Vol. 60, No. 17, 2012 Zhang et al.
October 23, 2012:1678–89 Functional Variants of NPYmatch (9/14 bp) for a consensus PAX6 (PAired boX gene 6)
motif, with the C-allele displaying a superior match (Fig. 1C,
Online Fig. 3). The chimp sequence suggests that the T
(less frequent)- allele is ancestral in humans. Association of
C-399T (rs16147) with responses to stress or emotional
challenge (15) as well as early onset atherosclerosis (21) have
Figure 2 Association of NPY Genetic Variation With Stress Phe
(A) NPY common haplotype TGTGC with plasma NPY concentration and blood pre
NPY as well as change in diastolic blood pressure (DBP) during environmental (col
DBP during the cold stress test. The genetic model was -allele recessive, on the
namic traits: systemic vascular resistance index (SVRI) or cardiac index (CI). The C
was calculated as systemic vascular resistance (SVR) normalized by BSA. The effe
reading frame.been reported, and C-399T lies within our NPY block ofLD (Online Fig. 2) as well as our trait-associated haplotypes
(Fig. 2A). However, we found no functional effects of
C-399T (Online Figs. 3 and 4). A recent functional study
found that the -399T (but not C-399) allele of an oligonu-
cleotide shifted mobility during EMSA (22); that study
employed nuclear protein extracts from postmortem human
pes in the Twins and Siblings
(BP) response to stress. (B) NPY promoter polymorphism 880 with plasma
ss. The deletion allele was associated with higher plasma NPY and change in
of inspection of the marker-on-trait results. (C) 880 with basal hemody-
calculated as cardiac output normalized by body surface area (BSA), and SVRI
the 2 traits are reciprocal. GEE  generalized estimating equation; ORF  opennoty
ssure
d) stre
basis
I was
cts onbrain rather than a chromaffin cell line.
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Functional Variants of NPY October 23, 2012:1678–89NPY promoter variation: coordinate directional functions
in transfected cells and in vivo (twins). In promoter/
luciferase reporter plasmids transfected into PC12 cells, we
studied the 2 common variants (880 and C399T),
giving rise to 4 combinations (haplotypes), here created by
site-directed mutagenesis: -C, -C, -T, and -T. Lu-
ciferase reporter basal (unstimulated) activity differed sub-
stantially across all 4 combinations (Online Fig. 5). -T
displayed the highest expression, with -T the lowest
(haplotype effect p  0.001). Two-way analysis of variance
for effects of the 2 SNP positions indicated a substantial
effect for 880 (p  0.001), although no effect for
C-399T. On either haplotypic background, the 880
allele increased gene expression significantly (p 0.001): by
approximately 16.2% on C-399 background and approxi-
mately 41.7% on 399T background, and the effects of the
880 allele on NPY expression were directionally coor-
dinate in transfected cells and in vivo (Online Fig. 6).
GRE at 880 in the NPY promoter: characterization.
NPY PROMOTER MOTIFS: COMPUTATIONAL DISRUPTION OF
GRE MOTIF BY COMMON VARIANT 880. The 880
2-bp, TG/—, Ins/Del) variant lies in a region relatively
onserved across species (especially in primates) with a partial
atch (8/12 bp) for a consensus GRE motif and the insertion
isplaying a superior match (Fig. 3A, left). The human ancestral
llele is likely the  (TG) version (i.e., the most frequent human
llele), on the basis of the chimp sequence, although the  (—)
ersion is recurrent in another primate, the orangutan.
PROMOTER 880: EXOGENOUS GLUCOCORTICOID AGONIST
(DEXAMETHASONE)ONREPORTERACTIVITY. Dexamethasone
decreased transfected NPY promoter activity (p  0.002)
(Fig. 3A, right) but only in the presence of the  allele at
880: by 37% (p  0.019) on -C and 20% (p  0.05) on
-T haplotypes. There was little or no effect of dexameth-
asone on haplotypes bearing the 880 -allele (-C or
-T haplotypes).
PROMOTER 880: EMSA AND ANTI-GLUCOCORTICOID
RECEPTOR SUPER-SHIFT. During EMSA, the labeled880
nsertion (, TG Ins) variant was more effectively shifted by
hromaffin cell nuclear proteins than the deletion (—, )
llele. One shifted band (see arrow in Fig. 3B) was com-
letely displaced by the unlabeled oligonucleotides and
Meta-Analysis of a Human NPY Promoter Variant on NPY SecretionTable 2 Meta-Analysis of a Human NPY Promoter Variant on NP
NPY RefSNP Group Allele_1/Allele_2 Freq_A1 n
rs3037354 Twins/sibs /TG 29.2% 39
rs3037354 MRS Marines /TG 26.0% 36
rs3037354 Meta-analysis /TG — 76
Additive linear models were tested by linear regression, with effect size expressed as beta (slope/al
StataCorp, College Station, Texas), with a fixed effect (i.e., genotype) on trait (NPY) model.
A1  allele_1 (-, less frequent allele); MRS  Marine Resilience Study; pNPY  plasma Neurop
-bp deletion allele.pproximately 90% diminished when an anti-glucocorticoideceptor (GR) antibody was added, suggesting specific
ecognition of the insertion allele by GR (Fig. 3B).
NPY GENETIC VARIATION IN SUBJECTS WITH THE MOST
EXTREME BP VALUES IN THE POPULATION. Here we studied
P trait-extreme individuals of European ancestry, to en-
ance statistical power (23,24). As in the twin/sib pairs, we
robed the 5 common polymorphisms (rs3037354, rs16147,
s16140, rs5573, and rs5574, MAF 20%) and 1 SNP in
he signal peptide (rs16139 Leu7Pro, MAF  2%), each in
Hardy-Weinberg equilibrium (Online Table 11), to span
the structural/functional domains across the gene (pro-
moter, exons, introns) in this case/control study.
HAPLOTYPE ASSOCIATION WITH BP. In the white BP-
extreme population, NPY also displayed 3 common haplo-
types (Online Table 12)—similarly as in twin/sib pairs—
among which the second-most common, TGTGC, was
associated with the quantitative BP traits (SBP and DBP in
mm Hg) as well as the dichotomous trait (higher and lower
BP) (Fig. 4A). Occurrence of haplotype TGTGC elevated
SBP from 127.4  1.0 mm Hg to 132.1  1.2 mm Hg
(increasing 3.7%, p  0.003), whereas DBP increased from
76.7  0.7 mm Hg to 79.3  0.8 mm Hg (increasing
3.45%, p  0.016) (Fig. 4A, left panel). Haplotype analysis
on subjects dichotomized into 2 BP groups (higher vs. lower
BP) indicated that individuals carrying common haplotype
TGTGC had a tendency to be hypertensive, with Fisher
exact test p  0.01 (Fig. 4A, right panel). The most
common haplotype (CCTAT) did not display an effect on
either the dichotomized or quantitative BP traits.
PROMOTER 880 AND BP. Single SNP-based allele tests
showed that promoter variant 880 (TG/—, Ins/Del)
yielded the maximal association with BP. In a  domi-
nant/ recessive model, both SBP (p  0.004) and DBP
(p  0.044) were increased in  carriers ( or /
genotype) (Fig. 4B, left panel), and such individuals also
were at increased risk for hypertension, with Fisher exact
test p  0.029 (Fig. 4B, right panel).
Discussion
NPY and stress: overview. The NPY is a sympathetic
co-transmitter co-stored with norepinephrine in large
cretion
Trait Model
Effect of SNP on Trait
Beta (Slope/Allele) SE of Beta p Value
pNPY Additive 7.10 2.54 0.006
pNPY Additive 7.86 2.47 0.00155
pNPY Additive 7.49 1.76 0.0001
SE of beta. Effects of rs3037354 across groups were evaluated with the META command in STATA
Y concentration; SNP  single nucleotide polymorphism; TG  2-base pair (bp) insertion allele;  Y Se
9
1
0
lele),dense-core vesicles, which when co-released triggers vaso-
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October 23, 2012:1678–89 Functional Variants of NPYconstriction via its Y1 receptor (25). Compared with nor-
epinephrine, NPY is preferentially released by intense or
prolonged sympathetic activation and therefore is a
marker of even more severe stress (26). Long-term
elevations of NPY might exhibit both detrimental and
beneficial consequences, such as resilience to and recovery
Figure 3 NPY Promoter 880 Polymorphism: GRE Motif
(A) The Neuropeptide Y (NPY) promoter variant 880 at the glucocorticoid resp
interspecies conservation, and consensus motifs match for GRE. Sequence alignm
Mapper and JASPAR (see Methods). Right panel: Functional response: effect of e
coal/dextran-stripped fetal bovine serum was used as the growth medium, to rem
added 6 h after transfection. Cells were harvested at 24 h after transfection. (B)
GRE with chromaffin cell nuclear proteins. The biotin-labeled insertion () allele ex
The binding signal for 1 band (arrow) was completely abolished by the unlabeled
glucocorticoid receptor (GR). ANOVA  analysis of variance.from post-traumatic stress disorder or dampening thefear response, allowing individuals to perform better
under extreme stress (27).
In this study, we began with genome-side linkage show-
ing that variation at the NPY locus itself determines NPY
secretion. Then systematic polymorphism determination at
the gene, coupled to heritable trait phenotyping in twin
element (GRE) motif. Left panel: NPY promoter 880 polymorphism:
were done by Clustal-W, whereas motifs from TRANSFAC were explored at Chip-
us glucocorticoid (dexamethasone) on NPY promoter activity in PC12 cells. Char-
y residual glucocorticoid from serum. Dexamethasone (Dex) (or vehicle) was
phoretic mobility shift assay (EMSA) interaction of 880 and the synthetic
increased binding to nuclear proteins, as compared with the deletion () version.
cleotide and inhibited approximately 90% by an antibody directed against theonse
ents
xogeno
ove an
Electro
hibits
oligonupairs, suggested a role for promoter Ins/Del polymorphism
N
w
t
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Functional Variants of NPY October 23, 2012:1678–89880 in NPY secretion and autonomic traits, with
replication in independent groups. Molecular biology doc-
umented that 880 disrupted a GRE. Finally, we
found that (880) associated with BP in the
population.
Heritable control of NPY secretion by the NPY gene in
twins, with replication. The NPY release is substantially
under substantial genetic control (h2  73 4%) (Table 1),
and a cis-quantitative trait loci on chromosome 7p15 was
identified with multipoint linkage analysis in twin and sib
pairs (Fig. 1A). Subsequently, we found that common
promoter variant880 associated with elevated NPY secretion
Figure 4 Association of NPY Genetic Variation With BP in the P
(A) NPY common haplotype TGTGC with hypertension. Left: TGTGC with systolic
higher SBP and DBP than those without it. Right: TGTGC with BP status. Absenc
hypertension (p  0.01). (B) NPY common promoter polymorphism 880 with
variant display higher SBP and DBP than insertion homozygotes. Right: 880 w
hypertensives; NT  normotensives; other abbreviations as in Figures 2 and 3.(Fig. 2B); this marker-on-trait association is consistent withfindings of Zhou et al. (15) in which subjects with NPY
haplotypes bearing allele 880 display higher plasma
PY, whereas haplotypes bearing allele 880 associated
ith lower plasma NPY. Indeed, we were able to replicate
he finding of NPY genetic determination on NPY secretion
in vivo in 2 independent samples, with effects consistent in
direction and magnitude, by meta-analysis (Table 2).
NPY gene and stress traits in twins. We found that the
880 allele is associated with not only NPY secretion and
pressor response to environmental (cold) stress (which in
longitudinal studies associated with later elevations in rest-
ing BP [28]) (Fig. 2B) but also basal hemodynamic status
ation
pressure (SBP) and DBP. Individuals who carry this haplotype display both
is haplotype is associated with normal BP, whereas presence is associated with
ension. Left: 880: effect on SBP and DBP. Subjects carrying the deletion
status. The deletion version is associated with hypertension (p  0.029). HT opul
blood
e of th
hypert
ith BP(systemic vascular resistance and CI) in a healthy twin
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October 23, 2012:1678–89 Functional Variants of NPYsample (Fig. 2C), progressing to elevated basal SBP/DBP in
population sample (Fig. 4B).
Glucocorticoids, NPY gene expression, and BP. Here we
found that the insertion () version of NPY promoter
ariant 880 created a partial match (8/12 bp) for a
RE motif (Fig. 3A, left), and the  element responded
unctionally to glucocorticoid (Fig. 3A, right) by binding
he GR (Fig. 3B). Previous promoter studies indicated that
he 880 variant lies within a region containing a
egative regulatory element, because elimination of the
egion between 1078/796 bp resulted in approximately
-fold increased transcription (29). We studied NPY tran-
cription in PC12 (rat pheochromocytoma) cells and found
hat promoter activity decreased after glucocorticoid (Fig. 3A,
ight). This decline is consistent with previous findings that
reatment with dexamethasone reduced NPY messenger
ibonucleic acid accumulation in cultured human pheochro-
ocytoma cells (30). Targeted ablation of the GR in the
ervous system of transgenic mice results in a significant
ncrease of NPY expression (31). Cortisol reduced and
he glucocorticoid antagonist metyrapone increased NPY
xpression in fish brain (32). In an anatomically defined
tudy, dexamethasone increased adrenal capsular NPY,
ith reversal by simultaneous administration of ACTH;
n the medulla, however, dexamethasone decreased NPY
ontent (33).
PY and BP regulation. Exogenous NPY exerts either
ypertensive (peripheral) or hypotensive (central) effects,
epending on the site of its administration. When admin-
stered centrally, the peptide displays sympatholytic, hypo-
ensive, and anxiolytic effects (34,35). In contrast, acute
dministration of NPY into the systemic circulation in-
reases BP (36). In humans and animals, NPY secretion
ncreases in response to cold exposure, tissue injury and
Figure 5 Schema
NPY genetic variation: consequences for autonomic physiology and cardiovascular
integrating the overall rationale and experimental results, and suggests futureschemia, hemorrhagic shock, and treadmill exercise, par-
icularly when combined with hypoxia (37). Elevated NPY
ecretion is found in a variety of conditions with sympa-
hetic hyperactivity such as hypertension, congestive heart,
nd renal failure (26). Moreover, at even lower than vaso-
onstrictor concentration, NPY stimulates vascular smooth
uscle cell proliferation (38).
Here we found that haplotypes across the NPY locus
ssociated with not only pressor responses (Fig. 2A) but also
asal SBP and DBP as well as hypertension status (Fig. 4A),
nd the peak effect occurred for promoter variant 880
Figs. 2B and 4B), at which the  allele was associated with
igher BP.
tudy strengths. We used the classical twin design in the
earch for trait-associated polymorphisms (39), beginning
ith genome-wide sib pair linkage (Fig. 1A). Multiple
utonomic phenotypes were measured in the twins, permit-
ing estimation of trait heritability as well as definition of
ffects of particular genetic variants at NPY on such heritable
intermediate phenotypes” (Table 1); dual documentation of
eritability and association lends internal consistency to the
pproach. Rather than using HapMap “tagging” SNPs, we
ystematically scanned the NPY locus for common or
nusual variants in functional gene regions (exons, untrans-
ated regions, and promoter). This approach allowed us to
ssociate variants in potentially active regions with physio-
ogical traits in vivo and then pursue the functional conse-
uences of such variants in reporter assays in cella (Figs. 2 to 4).
inally, we were able to replicate our effects on NPY secretion
n vivo with an additional 2 independent cohorts (Table 2).
tudy limitations. Although we conducted systematic
olymorphism determination in 4 diverse ethnic groups, our
tudies on autonomic physiology and disease were con-
ucted only in subjects of European ancestry, because allelic
se. The schematic presents a hypothetical framework
ions for exploration. Abbreviations as in Figures 2 and 3.disea
quest
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Functional Variants of NPY October 23, 2012:1678–89association studies can be susceptible to artifactual conclu-
sions resulting from even inapparent population admixture
(40); studies of additional ethnic or population groups will
be required to evaluate whether our NPY results are of more
general importance in the overall population. False positive
(type I) statistical errors might occur during genetic associ-
ations, because the effects of multiple genetic variants might
be evaluated on traits. We guarded against such errors in
several ways: we began with genome-wide linkage, and then
proceeded to haplotype analysis, achieving genetic effects
first on NPY secretion with genome-wide stringency (Fig. 1A)
and then on population BP (Fig. 4A) without multiple
testing. Moreover, we extended our effects to 3 independent
subject groups; the same NPY promoter allele associated
with higher basal population BP also associated with “inter-
mediate phenotypes” for hypertension in independent groups:
elevated NPY secretion, exaggerated BP response during
stress, higher systemic vascular resistance and lower CI, each of
which might be “intermediate” phenotypes for development of
high BP in the population (Figs. 2A and 2B).
onclusions and Perspectives
ommon genetic variation at the NPY locus, particularly at
romoter 880, alters glucocorticoid responses and so
nfluences NPY expression as well as systemic vascular
esistance, later the early heritable response to environmen-
al stress, and ultimately resting BP in the population.
lthough causal inferences in this proposed chain of events
re not yet established, we illustrate a proposed pathway
schematized in Fig. 5) that integrates our conceptual
pproach with application to the NPY system; this pathway
ields testable predictions for future experimental verifica-
ion. These results point to new molecular strategies for
robing autonomic control of the circulation and ultimately
he susceptibility to and pathogenesis of cardiovascular and
europsychiatric disease states.
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